Xu et al. [22] detected highly expressed EBV-miR-BART13 in the serum samples of NPC patients, which can directly target NF-κB inhibitor interacting Ras-like 2 (NKIRAS2) to promote the expression of the NF-κB signaling pathway and increase cell proliferation and migration (Fig. 1). This evidence concerns the gene NFKB1 and nasopharyngeal carcinoma.